AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05562921 — intervention group
Intervention type: BEHAVIORAL
Intervention: Cases-remote patient monitoring prescribed
Description: Cases: patients prescribed remote patient monitoring for blood pressure during routing care delivery
Study NCT00238290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab + Letrozole
Description: Patients receive trastuzumab (Herceptin®) IV over 30-90 minutes once in weeks 1-3 OR once in week 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients experiencing disease progression after 9 weeks receive trastuzumab as before and oral letrozole once daily in the absence of further disease progression or unacceptable toxicity.
Study NCT02838238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Study NCT02838238 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03355456 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency ablation
Description: Ablation procedure to eliminate atrial fibrillation
Study NCT00610519 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: mixture of aromatic essential oils.
Description: 3% of mixture containing aromatic essential oils of Eucalyptus citriodora, Eucalyptus globulus, Mentha piperita, Origanum syriacum, and Rosmarinus Officinalis, spraying to the throat.
Study NCT00610519 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 0:1% of Lemon VIP (Florasynth,Israel), spraying to the throat.
Study NCT00002874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bicalutamide
Description: One (150 mg) tablet by mouth daily for two years beginning immediately upon, or just prior to, the initiation of irradiation.
Study NCT00002874 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: 64.8 Gy in 36 fractions (1.8 Gy in 5 daily sessions per week) to the original prostate volume, the tumor resection bed, and the proximal membranous urethra.
Study NCT00002874 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: radiation therapy
Description: 64.8 Gy in 36 fractions (1.8 Gy in 5 daily sessions per week) to the original prostate volume, the tumor resection bed, and the proximal membranous urethra.
Study NCT00002874 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: One tablet by mouth daily for two years beginning immediately upon, or just prior to, the initiation of irradiation.
Study NCT02530242 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: End-tidal Carbon Monoxide Subjects
Description: ETCO monitor will be used to measure CO levels in subjects and controls.
Study NCT02530242 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: End-tidal Carbon Monoxide Controls
Description: ETCO monitor will be used to measure CO levels in subjects and controls.
Study NCT02195323 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intravenous injection
Description: Intravenous injection of bone marrow derived MSC in patients with CKD.
Study NCT00136474 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amifostine
Description: Given 30-60 minutes prior to daily radiation therapy
Study NCT00136474 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy
Description: Daily radiation therapy
Study NCT00839826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (BAY59-7939)
Description: 2,5 mg bid,5 mg bid,10mg bid, 20 mg bid, 20 mg tid, 30 mg bid, dose escalation trial
Study NCT00839826 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: 40 mg bid
Study NCT02624089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Ropivicaine will be administered via in-line nebulization using the Aeroneb Pro™ system
Study NCT02624089 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline will be administered via in-line nebulization using the Aeroneb Pro™ system
Study NCT02416141 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fast release oro dispersible tramadol 50 mg
Description: idem arm 1
Study NCT02233088 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ELM Group
Description: ELM participants are trained to portion their meals according to the Perfect Plate method, a modified version of the USDA's ChooseMyPlate.gov. The stress management focuses on mindful living, cognitive restructuring; the enhancement of positive emotions. The physical activity component focuses on reduction of sedentary activity (by increasing daily step counts) and moderate-to-vigorous physical activity.
Study NCT02233088 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: ELM Classes
Description: ELM classes will be administered through Rush Generations program and focus on health education.
Study NCT02233088 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ELM Individual
Description: ELM Individual arm participants will receive education materials on metabolic syndrome and diet, exercise, stress reduction recommendations. The participants will be recommended to follow these guidelines and discuss/seek support from their health care provider (visits at baseline, 3 and 6 months will be recommended.
Study NCT04441398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitazoxanide
Description: Subjects will receive nitazonanide 600 mg TID for 7 days. Treatment can be extended for another 7 days at Investigators discretion.
Study NCT04441398 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive placebo TID for 7 days. Treatment can be extended for another 7 days at Investigators discretion.
Study NCT00665639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: micafungin
Description: IV
Study NCT00665639 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: caspofungin
Description: IV
Study NCT04042428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somatropin injection
Description: Subjects receive a daily subcutaneous dose of 0.2 IU/kg (0.067 mg/kg) of recombinant somatropin (rhGH) during 14 days.
Study NCT03251105 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: supraglottic airway intubation
Study NCT01483651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucagon
Description: The first dose of glucagon will be delivered approximately one hour after infusion of IV insulin has started. The subsequent three doses will be delivered every two hours. The dosage will depend on the IV insulin infusion (50 units regular insulin in 499.5 mL 0.9% saline): Study 1) insulin 0.01 units/kg/hour and glucagon doses (ug): 10,25,45,70; Study 2) insulin 0.02 units/kg/hr and glucagon doses (ug): 25,45,70,100; Study 3) insulin 0.04 units/kg/hr and glucagon doses (ug): 45,70,100,135; Study 4) insulin 0.08 units/kg/hr and glucagon doses (ug): 70,100,135,175. Insulin levels and glucagon doses will be randomized. Glucagon will be reconstituted with 10 mL of sterile water and administered subcutaneously.
Study NCT03265392 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Water
Description: 250 mL of water
Study NCT03265392 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Lemon juice
Description: 250 mL of lemon juice
Study NCT04453150 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alternate-day fasting
Description: Alternate-day fasting
Study NCT04453150 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ketogenic diet
Description: Ketogenic diet
Study NCT05283733 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: reverse conversion technique
Description: converting open appendectomy to laparoscopic technique for proper control of intraabdominal sepsis
Study NCT04549987 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Space closure without changing working archwire monthly
Description: Upper premolar space closure using the same 0.019X0.025 stainless steel archwire every month
Study NCT01483651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Insulin was administered at a low, medium or high infusion rate. The intervention sequence was randomly pre-determined for all participants.
Study NCT06522802 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: balance tests, reaction time evaluation
Description: Only 3 tests were applied to participants
Study NCT04483037 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bowklean
Description: assigned intervention
Study NCT04483037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bowklean
Description: assigned intervention
Study NCT03265392 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Tea
Description: 250 mL of tea
Study NCT03265392 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Peas
Description: 20 peas
Study NCT01563822 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Follicular fluid
Description: The intervention is flushing the uterine cavity with 2 ml of clear follicular fluid surrounding mature oocytes after ovum pick-up through an IUI catheter
Study NCT00401024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Study NCT00401024 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Study NCT00401024 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Study NCT03383731 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group 1
Description: the surgical method of standard 3-port 23 gauge pars plana vitrectomy + internal limiting membrane peeling + air-fluid exchange + silicone oil infusion
Study NCT03383731 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Group 2
Description: the surgical method of standard 3-port 23 gauge pars plana vitrectomy + internal limiting membrane peeling + inverted internal limiting membrane insertion + air-fluid exchange
Study NCT02771691 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mentalization-Based Group Therapy for Adolescents
Study NCT01917773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide
Description: Average MI for all patients was calculated over 15-minutes, 30-minutes and 45- minutes before and after administration of octreotide
Study NCT01917773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisacodyl
Study NCT01341041 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: chlorine dioxide
Description: one time wash with 50ppm CD solution
Study NCT01341041 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: saline
Description: one time wash with 50-100 cc normal saline
Study NCT00694122 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lantus (glargine)
Description: Described in Arm Description
Study NCT03768297 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: dual zone concept
Description: immediate implant with bone fill till soft tissue level
Study NCT03768297 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dual zone concept
Description: immediate implant with bone fill till soft tissue level
Study NCT01710371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-AV-133
Description: 296 MBq (8 mCi)
Study NCT01710371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10% Arginine Hydrochloride-R-Gene 10
Study NCT04693026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remdesivir
Description: Remdesivir 100 IV Infusion as a lyophilized powder
Study NCT04693026 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remdesivir
Description: Remdesivir 100 IV Infusion as a lyophilized powder
Study NCT04693026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Baricitinib oral tablet form
Study NCT04693026 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tocilizumab
Description: Tocilizumab IV Infusion
Study NCT01139424 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: endoscopic suturing
Description: endoscopic suturing of the anastomotic leak
Study NCT03800810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid
Study NCT04324489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAS181
Description: Patient receives nebulized DAS181 (4.5 mg BID/day, a total 9 mg/day) for 10 days.
Study NCT01197027 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard counseling
Description: Standard HIV counseling
Study NCT01197027 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard counseling
Description: Standard HIV counseling
Study NCT04713995 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Dietary recommendations
Description: Dietary recommendations based on microbiome analysis of samples will be given and expected to receive and report in \~3 months survey after following recommendations.
Study NCT00086307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramipexole
Description: Pramipexole will be titrated so patients receive the following medication three times per day during the weeks noted: .125 milligrams (mg) in week 1, .250 mg in week 2, .5 mg in week 3, and .75 mg in weeks 4 to 6.
Study NCT03800810 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Mesenchymal Stem Cell
Study NCT03800810 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Human Somatropin
Study NCT02040636 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetanus and Diphtheria Toxoids Adsorbed Combined with Component Pertussis Vaccine and IPV
Description: 0.5 mL, Intramuscular
Study NCT02040636 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tetanus and Diphtheria Toxoids Adsorbed Combined with Component Pertussis Vaccine and IPV
Description: 0.5 mL, Intramuscular
Study NCT02040636 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine
Description: 0.5 ml, Intramuscular
Study NCT02040636 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hepatitis B vaccine
Description: 0.5 ml, Intramuscular
Study NCT02219113 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arthroscopic surgery
Study NCT00086307 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pramipexole
Description: Pramipexole will be titrated so patients receive the following medication three times per day during the weeks noted: .125 milligrams (mg) in week 1, .250 mg in week 2, .5 mg in week 3, and .75 mg in weeks 4 to 6.
Study NCT00086307 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: Escitalopram will be started at 10 mg/day and patients will continue on this throughout the study.
Study NCT00086307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: Escitalopram will be started at 10 mg/day and patients will continue on this throughout the study.
Study NCT02219113 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liposuction
Study NCT02219113 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ADRC isolation
Description: ADRC isolation performed using Celution 800/CRS System (Cytori Therapeutics Inc) according to manufacturer's protocol
Study NCT03334266 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Spirit Nurture (FSN)
Description: The FSN home-visiting module consists of 36 60-minute lessons delivered by trained local FHCs, from 28 weeks gestation to 18 months postpartum. The lessons focus on three key content domains: 1) promotion of optimal breastfeeding, complementary and responsive feeding across early childhood; 2) promotion of healthy infant/toddler diet and physical activity, as well as reduced screen time and sedentary lifestyle; and 3) promotion of maternal psychosocial well-being, optimization of healthy food/beverage availability and identification/creation of safe play spaces in the home environment.
Study NCT03334266 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Injury Prevention Education (IPE)
Description: The control group will receive Injury Prevention Education (IPE). The IPE home-visiting module consists of 8 30-minute lessons delivered by trained local Family Health Liaisons (FHL), from 28 weeks gestation to 18 months postpartum. Injury prevention lessons focus on injury prevention topics relevant to the participating communities, including: motor vehicle safety for mothers and children; preventing scald burns; fire safety; child-proofing a home; preventing falls; preventing poisonings; and preventing animal bites.
Study NCT03334266 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Optimized Standard Care (OSC)
Description: OSC will be available to both in the FSN intervention and control groups. OSC consists of transportation assistance to prenatal and well-baby clinic visits as recommended by the Indian Health Service (IHS) and American Academy of Pediatrics (AAP) and rescue services through linkages to community agencies as needed.
Study NCT03334266 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optimized Standard Care (OSC)
Description: OSC will be available to both in the FSN intervention and control groups. OSC consists of transportation assistance to prenatal and well-baby clinic visits as recommended by the Indian Health Service (IHS) and American Academy of Pediatrics (AAP) and rescue services through linkages to community agencies as needed.
Study NCT01127061 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: 4 months of exercise training that is custom-designed based on individual cardiopulmonary stress test data. Regimen starts at low intensity (60% of heart rate reserve) and frequency (20 minutes, 3 days per week) and increases with a goal of 70% of heart rate reserve and exercising 60 minutes 4-7 days per week.
Study NCT04549987 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Space closure withchanging working archwire monthly
Description: Upper premolar space closure using new 0.019X0.025 stainless steel archwire every month
Study NCT01817010 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multi-Component Rehabilitation (CMC)
Study NCT01817010 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control (CON)
Study NCT03083912 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Fortimel Complete
Description: The residents included receive 2 bottle por day.
Study NCT02956889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vismodegib
Description: Patients will receive a continuous once-daily oral dosing of Vismodegib at a dosage of 150 mg .
Study NCT02956889 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy (RT) will be administered with a total dose of 50 Gy/2.5 Gy per fraction over 4 weeks.
Study NCT02990884 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ketamine
Study NCT00321412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AST-120
Description: oral, sachet, 2 grams three times daily for 8 weeks
Study NCT03450772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Creon® 25000
Description: Experimental drug
Study NCT03450772 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Creon® 10000
Description: Active comparator
Study NCT00501319 — intervention group
Intervention type: BEHAVIORAL
Intervention: Interactive Voice Response (IVR)
Description: Phone calls once weekly for the first 3 months after surgery, then every two weeks for an additional 3 months.
Study NCT00501319 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Questionnaires taking 20 minutes to complete.
Study NCT04062955 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: Receive dietary counseling
Study NCT04062955 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dual X-ray Absorptiometry
Description: Undergo DXA scan
Study NCT00272779 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LPV
Description: 400 mg (3 133mg capsules) BID for 96 weeks
Study NCT01665586 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: dexmedetomidine
Description: Spinal anesthesia regimen Group F: 6mg bupivacaine + 20mcg fentanyl (intrathecal) + o.4 cc 5% dextrose water Group C: 6mg bupivacaine + 0.4 cc normal saline + 0.4cc 5% dextrose water~dexmedetomidine 0.2\~0.8 micro gram/kg intravenous administration after the sterilization of the spinal anesthesia level, and prehydration
Study NCT01665586 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexmedetomidine
Description: Spinal anesthesia regimen Group F: 6mg bupivacaine + 20mcg fentanyl (intrathecal) + o.4 cc 5% dextrose water Group C: 6mg bupivacaine + 0.4 cc normal saline + 0.4cc 5% dextrose water~dexmedetomidine 0.2\~0.8 micro gram/kg intravenous administration after the sterilization of the spinal anesthesia level, and prehydration
Study NCT02526121 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Phlebotomy
Description: Volume of 400 mL every 3 weeks, 3 times.
Study NCT02526121 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary and lifestyle counseling.
Description: Dietary and lifestyle counseling.